BASIC PRINCIPLES OF PERIPROCEDURAL MANAGEMENT OF PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION RECEIVING ANTICOAGULANT THERAPY: THE CONSENSUS DOCUMENT OF EXPERTS OF THE AMERICAN COLLEGE OF CARDIOLOGY

The article contains an outline of the 2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation. This document considers in detail problems of necessity and safety of temporary interrupting of anticoagulation for the period of procedure, main principles of interruption and restarting anticoagulant therapy after procedure, indications to the transitional (bridging) therapy in the periprocedural period, as well as possible strategies of periprocedural management of patients in dependence of risk of bleeding and thromboembolic complications. This Expert Consensus Decision Pathway refer to the periprocedural use of both oral (vitamin K antagonists, new oral anticoagulants) and parenteral (unfractionated and low-molecular-weight heparins) anticoagulants.

фибрилляция предсердий, антикоагулянты, переходная терапия, новые пероральные антикоагулянты, антагонисты витамина К, перипроцедурное ведение, atrial fibrillation, anticoagulants, transitional therapy, new oral anticoagulants, vitamin K antagonists, periprocedural management

1. Doherty J. U., Gluckman T.J., Hucker W.J. et al. 2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation: A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force. J Am Coll Cardiol 2017;69 (7):871-898. doi: 10.1016/j. jacc. 2016.11.024.

2. Spyropoulos A. C., Douketis J. D. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 2012;120:2954-2962.

3. Baron T. H., Kamath P. S., McBane R. D. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med 2013;368:2113-2124.

4. Eisen G. M., Baron T. H., Dominitz J. A. et al. Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures. Gastrointest Endosc 2002;55:775-779.

5. Douketis J. D., Spyropoulos A. C., Kaatz S. et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 2015;373:823-833.

6. Steinberg B. A., Peterson E. D., Kim S. et al. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation 2015;131:488-494.

7. Beyer-Westendorf J., Gelbricht V., Forster K. et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J 2014;35:1888-1896.

8. Dunn A. S., Spyropoulos A. C., Turpie A. G. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Perioperative Enoxaparin Cohort Trial (PROSPECT). J Thromb Haemost 2007;5:2211-2218.

9. Spyropoulos A. C., Turpie A. G., Dunn A. S. et al. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost 2006;4:1246-1252.

10. Healey J. S., Eikelboom J., Douketis J. et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation 2012;126:343-348.

11. Sherwood M. W., Douketis J. D., Patel M. R. et al. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke And Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation 2014;129:1850-1859.

12. Garcia D., Alexander J. H., Wallentin L. et al. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood 2014;124:3692-3698.

13. Douketis J., Weitz J. I., Murphy S. et al. Perioperative adverse outcomes in patients with atrial fibrillation taking edoxaban or warfarin: analysis of the ENGAGE-AF TIMI 48 Trial (abstr). J Am Coll Cardiol 2015;65: A2092.

14. Narouze S., Benzon H. T., Provenzano D. A. et al. Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications: guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med 2015;40:182-212.

15. Eikelboom J. W., Connolly S.J., Brueckmann M. et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369:1206-1214.